Role of PGC-1-alpha-associated Mitochondrial Biogenesis in Statin-induced Myotoxicity

Login or register to view PDF.
Creative Commons Licence
 
Received date
14 May 2020
Accepted date
14 May 2020
Citation
European Cardiology Review 2020;15:e35.
DOI
https://doi.org/10.15420/ecr.2020.15.1.PO12
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Aim: Statins are well tolerated but can be associated with mitochondrial dysfunction in skeletal muscles. Statins impair mitochondrial proliferation by decreasing PGC-1α expression in human and rat skeletal muscle, suggesting a role of PGC-1α in statin-induced myotoxicity. This study aimed to investigate these effects in differentially expressed PGC-1α mouse models.

Methods: We used three mouse models: mice with muscle PGC-1α knockout (MKO), mice overexpressing PGC-1α (MCK), and wild-type (WT) mice. Mice were treated for 3 weeks with water or simvastatin (5 mg/kg/d) by oral gavage. We determined exercise capacity, muscle function and the function of muscle mitochondria from glycolytic gastrocnemius and soleus oxidative muscles.

Results: Simvastatin showed muscular impairments in WT mice, manifested by decreased exercise capacity, grip strength and mitochondrial respiration in the glycolytic muscle, coupled with increased H2O2 production. Moreover, MKO mice treated with simvastatin exacerbated these muscular dysfunctions and showed impaired mitochondrial respiration in oxidative and glycolytic muscle types. However, MCK mice showed no impairments in exercise capacity and muscle function.

Conclusion: Increased muscle PGC-1α expression ameliorated statin-induced muscular dysfunctions, while decreased muscle PGC-1α expression further exacerbated the toxicity. Therefore, PGC-1α seems to be a susceptibility factor and has an important role in mitigating simvastatin-induced myotoxicity.